HGD Deficiency | Homogentisic Acid | Ochronotic Pigment | Spine-First Arthropathy
Systems Affected by Ochronotic Pigment
Critical Must-Knows
- Autosomal recessive deficiency of homogentisate 1,2-dioxygenase (HGD) in the tyrosine pathway
- Homogentisic acid (HGA) accumulates, polymerises and binds collagen as a dark ochronotic pigment
- Black urine from birth, but arthropathy and pigment (ochronosis) appear only in the 4th decade
- Spine is affected first: disc calcification and narrowing precede peripheral joint disease
- Nitisinone (a HPPD inhibitor) lowers HGA by ~99% but causes tyrosinaemia/keratopathy
Clinical Pearls
- "Classic triad: dark urine, ochronotic pigmentation, ochronotic arthropathy
- "Diagnosis confirmed by elevated urinary homogentisic acid
- "Disc calcification with vacuum phenomena is the hallmark spine radiograph
- "Differentiate from ankylosing spondylitis: AKU spares sacroiliac joints early and is HLA-B27 negative
Clinical Imaging
Critical Ochronosis Exam Points
The Enzyme Defect
Homogentisate 1,2-dioxygenase (HGD) deficiency, autosomal recessive. Blocks tyrosine catabolism so homogentisic acid (HGA) cannot be converted to maleylacetoacetate. HGA accumulates and is excreted, but excess polymerises into pigment.
Pigment to Pathology
HGA-derived polymer binds collagen in cartilage, discs, tendons, sclera, ear and heart valves. The dark deposit (ochronosis) stiffens and embrittles connective tissue, driving a secondary osteoarthritis (ochronotic arthropathy).
Spine First
Axial disease precedes peripheral disease. Lumbar/thoracic disc calcification, narrowing, vacuum phenomena and progressive ankylosis appear earliest. Large joints (knee, hip, shoulder) follow.
Mimic Alert
Do not call it ankylosing spondylitis. AKU is HLA-B27 negative, spares the sacroiliac joints early, and shows dense disc calcification rather than syndesmophytes/bamboo spine. Black urine on standing is the giveaway.
SCAREDWhere Ochronotic Pigment Deposits
| S | Spine and Sclera Disc calcification (first); slate-blue scleral pigment |
| C | Cartilage Articular cartilage and ear (pinna) cartilage |
| A | Aortic valve Valve and root pigment, stenosis, calcification |
| R | Renal/prostate stones HGA-related stone disease |
| E | Ear Blue-grey pigment of the pinna; dark cerumen |
| D | Discs and tenDons Disc narrowing; tendons embrittled (Achilles rupture) |
| S | Spine and Sclera Disc calcification (first); slate-blue scleral pigment | A | Aortic valve Valve and root pigment, stenosis, calcification | E | Ear Blue-grey pigment of the pinna; dark cerumen |
| C | Cartilage Articular cartilage and ear (pinna) cartilage | R | Renal/prostate stones HGA-related stone disease | D | Discs and tenDons Disc narrowing; tendons embrittled (Achilles rupture) |
Hook:Connective tissue gets SCARED black by homogentisic acid pigment.
Overview
Alkaptonuria (AKU) is a rare autosomal recessive inborn error of tyrosine metabolism. The downstream connective-tissue disease it causes is ochronosis, and the resulting joint disease is ochronotic arthropathy. The condition is defined by a triad that an examiner expects you to recite: dark urine, ochronotic pigmentation of connective tissue, and a progressive arthropathy.
The key conceptual point is the time course. Because the enzyme block is present from birth, the urine darkens on standing from infancy. However, the pigment that damages tissue takes decades to accumulate, so ochronosis and arthropathy are usually silent until the fourth decade of life. Patients therefore often present to orthopaedics with "early, severe, spine-dominant osteoarthritis" long before the metabolic diagnosis is made.
Why Ochronosis Matters in an Orthopaedic Exam
Ochronosis is a favourite basic-science and viva topic because it links a single enzyme defect to a recognisable arthropathy, a classic spine radiograph, a named disease-modifying drug (nitisinone) and several "spot diagnosis" signs (scleral and ear pigment, black urine, dark cartilage seen intra-operatively). It rewards candidates who can move smoothly from biochemistry to imaging to management.
The Diagnostic Triad
- Dark urine: turns black on standing or with alkali
- Ochronosis: blue-grey pigment in sclera, ear, skin
- Arthropathy: spine-first secondary osteoarthritis
Spot Diagnosis Clues
- Intra-operative: jet-black cartilage at arthroplasty
- Sclera: slate-blue pigment (between cornea and canthus)
- Pinna: blue-grey, thickened, leathery ear cartilage
- History: stained nappies/underwear since childhood
Mechanism, Pathophysiology and Core Concepts
The Tyrosine Degradation Pathway
Phenylalanine and tyrosine are catabolised through a sequential enzymatic pathway. Ochronosis is caused by a block at a single step.
Sequence:
- Phenylalanine to tyrosine (phenylalanine hydroxylase)
- Tyrosine to 4-hydroxyphenylpyruvate (tyrosine aminotransferase)
- 4-hydroxyphenylpyruvate to homogentisic acid (HGA) (4-hydroxyphenylpyruvate dioxygenase, HPPD)
- HGA to maleylacetoacetate (the BLOCKED step in AKU) - requires homogentisate 1,2-dioxygenase (HGD)
- Maleylacetoacetate eventually to fumarate and acetoacetate
The deficient enzyme is HGD (chromosome 3q13), an autosomal recessive defect. With HGD absent, HGA cannot be opened to maleylacetoacetate and accumulates massively.
| Enzyme | Reaction | Status in AKU | Therapeutic Relevance |
|---|---|---|---|
| HPPD (4-HPP dioxygenase) | Makes HGA (upstream) | Active | Target of nitisinone - block it to reduce HGA |
| HGD (homogentisate 1,2-dioxygenase) | Breaks down HGA | Deficient - the primary defect | The missing enzyme |
This pathway logic is what makes nitisinone rational therapy.
Classification and Patterns of Involvement
There is no single named "classification" of ochronosis, but examiners expect you to organise the disease by system involvement and by the typical sequence in which sites are affected.
| Site | Typical Finding | Timing | Clinical Note |
|---|---|---|---|
| Lumbar/thoracic spine | Disc calcification, narrowing, vacuum phenomena, ankylosis | Earliest | Most disabling; precedes peripheral disease |
| Large peripheral joints | Ochronotic OA of knee greater than hip greater than shoulder | After spine | Black cartilage seen at arthroplasty |
| Sacroiliac joints | Relatively spared early | Late | Helps distinguish from ankylosing spondylitis |
| Cardiac valves/aorta | Aortic valve pigment, calcification, stenosis | Mid-late | Needs echocardiographic surveillance |
| Tendons | Embrittlement, spontaneous rupture (e.g. Achilles) | Variable | Pigmented tissue at repair |
| Sclera / ear / skin | Blue-grey ochronotic pigment | From 4th decade | Visible spot-diagnosis signs |
| Renal / prostate | Stones (HGA-related) | Variable | Can be the presenting feature |
Distinguishing AKU from Ankylosing Spondylitis
Both can cause a stiff, fused spine, but the mechanisms differ. AKU: HLA-B27 negative, dense disc calcification, early sparing of the sacroiliac joints, black urine. Ankylosing spondylitis: HLA-B27 associated, syndesmophytes/bamboo spine, early bilateral sacroiliitis, no urinary colour change.
Clinical Presentation
Age and Mode of Presentation
- Infancy/childhood: dark-staining urine (nappies, underwear) - often the only sign and frequently missed.
- Fourth decade onward: insidious low back pain and stiffness; progressive large-joint pain.
- Spot signs: scleral and ear pigment, blue-grey skin over sweat-gland-rich areas, dark cerumen.
Musculoskeletal Features
- Axial: chronic low back pain, reduced spinal mobility, loss of lumbar lordosis, progressive stiffening toward ankylosis.
- Peripheral: large-joint osteoarthritis (knee most common), effusions, mechanical symptoms from cartilage fragments.
- Tendon: spontaneous rupture (classically the Achilles) due to embrittlement.
Extra-articular Features
- Cardiac: aortic valve pigmentation, stenosis and aortic root involvement; coronary and valvular calcification.
- Genitourinary: renal and prostatic calculi.
- Ophthalmic/cutaneous: scleral pigment, pigmented pinna, skin discolouration.
Look beyond the joint
A patient presenting with severe, early, spine-dominant osteoarthritis plus a heart murmur or renal stones should prompt consideration of ochronosis. The aortic valve disease can be clinically important and warrants echocardiographic assessment.
Investigations
Confirming the Diagnosis
The diagnosis is biochemical and centres on demonstrating homogentisic acid.
- Elevated urinary homogentisic acid (HGA): the diagnostic test; quantified by gas chromatography-mass spectrometry.
- Urine darkening: classic bedside clue - urine turns black on standing or on alkalinisation (oxidation of HGA).
- Serum HGA and tyrosine: measurable; tyrosine becomes especially relevant when monitoring nitisinone therapy.
- HGD gene analysis: confirms the autosomal recessive defect; many pathogenic variants described worldwide.
The bedside test
Adding alkali (or simply leaving the sample to stand and oxidise) turns alkaptonuric urine black. It is a memorable demonstration but quantitative urinary HGA is the definitive test.
Biochemistry, not imaging, makes the definitive diagnosis.
DUOAlkaptonuria Diagnostic Triad
| D | Dark urine Black on standing/alkalinisation; raised urinary HGA is definitive |
| U | Undermined connective tissue Ochronotic pigmentation of sclera, ear, cartilage and valves |
| O | Osteoarthropathy Spine-first ochronotic arthropathy, then large joints |
| D | Dark urine Black on standing/alkalinisation; raised urinary HGA is definitive |
| U | Undermined connective tissue Ochronotic pigmentation of sclera, ear, cartilage and valves |
| O | Osteoarthropathy Spine-first ochronotic arthropathy, then large joints |
Hook:The DUO of pigment plus arthropathy on a background of dark urine = alkaptonuria.
Management
Management has two arms: disease-modifying metabolic therapy to reduce HGA, and supportive/orthopaedic care for established connective-tissue damage that pigment has already caused.
Nitisinone (HGA-lowering therapy)
Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase (HPPD), the enzyme upstream of the block. By preventing HGA formation it dramatically reduces the substrate that drives ochronosis.
- Efficacy: in the SONIA 2 randomised trial, 10 mg daily reduced 24-h urinary HGA by ~99.7% at 12 months and slowed clinical disease progression (lower cAKUSSI score at 48 months) versus no treatment.
- Dose-response: SONIA 1 showed a clear dose-dependent fall in urinary HGA across 1-8 mg, with ~99% reduction at 8 mg.
- Caveat - acquired tyrosinosis: blocking HPPD raises tyrosine in serum and tissues, risking corneal keratopathy (potentially sight-threatening) and prompting attention to diet.
Nitisinone trade-off
Nitisinone is highly effective at lowering HGA but causes hypertyrosinaemia/tyrosinosis. Patients require tyrosine monitoring, ophthalmic vigilance for keratopathy, and often dietary protein modification to mitigate the tyrosine rise.
The drug treats the cause but introduces a new metabolic problem to manage.
Complications
Axial Disability
Progressive disc calcification, narrowing and ankylosis cause chronic back pain, loss of spinal mobility and, rarely, neurological compromise.
Peripheral Arthropathy
Premature, severe osteoarthritis of large joints (knee, hip, shoulder) often requiring multiple arthroplasties.
Cardiac Disease
Aortic valve pigmentation, stenosis and root involvement; valvular and vascular calcification needing surveillance and sometimes replacement.
Tendon Rupture
Embrittled tendons (classically Achilles) can rupture spontaneously; tissue is pigmented and friable at repair.
Stone Disease
Renal and prostatic calculi related to HGA, occasionally the presenting feature.
Treatment-Related
Nitisinone-induced hypertyrosinaemia can cause corneal keratopathy and, with very high tyrosine, neurocognitive concerns - hence monitoring.
Clinical Relevance
The Surgeon's Perspective
Ochronosis is the rare metabolic disease that an orthopaedic surgeon is genuinely likely to encounter at the operating table. The first clue is often black cartilage discovered unexpectedly during arthroplasty in a patient labelled as having "primary" osteoarthritis. Recognising this prompts the metabolic diagnosis, family screening and systemic assessment (especially the aortic valve).
Why the Spine Comes First
The intervertebral disc is rich in type II collagen and proteoglycan and has a high collagen turnover environment that favours pigment binding. The result is the characteristic multilevel disc calcification that distinguishes ochronotic spondylopathy from other causes of a stiff spine and predates peripheral disease.
A Model Disease for Metabolic Therapy
AKU is also a teaching example of rational drug design: because the defect is loss of a downstream enzyme, blocking the upstream enzyme (HPPD) with nitisinone reduces the toxic intermediate. The trade-off - accumulation of tyrosine - illustrates the principle that re-routing a metabolic pathway shifts, rather than abolishes, the metabolic burden.
Evidence Base
SONIA 2: Nitisinone Reduces HGA and Slows Progression
- 138 patients aged 25+ randomised 1:1 to nitisinone 10 mg daily or no treatment over 4 years
- Urinary HGA at 12 months fell by 99.7% with nitisinone versus control
- cAKUSSI clinical severity score rose significantly less with nitisinone at 48 months (adjusted difference -8.6 points)
- Well tolerated with no treatment-related deaths; supports nitisinone as a disease-modifying therapy
SONIA 1: Dose-Dependent HGA Lowering by Nitisinone
- 40 patients randomised to no treatment or nitisinone 1, 2, 4 or 8 mg daily for 4 weeks
- Clear dose-response: 24-h urinary HGA fell progressively across doses
- The 8 mg dose reduced urinary HGA by ~98.8% from baseline
- Tyrosine rose at all doses but no serious adverse events over 4 weeks
Exam Viva Scenarios
Use these scenarios to practise clinical reasoning and management decisions
Scenario 1: Black Cartilage at Arthroplasty
"During a total knee replacement for presumed primary osteoarthritis you encounter jet-black, brittle articular cartilage. The examiner asks how you interpret and act on this."
Diagnosis: Ochronosis from alkaptonuria. The black cartilage is melanin-like ochronotic pigment, formed from polymerised homogentisic acid (HGA) bound to collagen, due to autosomal recessive deficiency of homogentisate 1,2-dioxygenase (HGD).
Confirmation: Quantitative urinary homogentisic acid is the diagnostic test; the urine also darkens on standing or alkalinisation. HGD gene testing confirms the defect.
Systemic assessment: Examine for scleral and ear pigment, arrange echocardiography for aortic valve disease, screen for renal/prostatic stones, assess the spine, and offer family screening. Refer to a metabolic service to consider nitisinone.
Scenario 2: The Calcified Spine
"A 45-year-old presents with chronic back pain and a stiff spine. Radiographs show dense calcification of multiple intervertebral discs. The examiner asks you to characterise and differentiate the findings."
Radiograph: Multilevel dense intervertebral disc calcification with disc-space narrowing, vacuum phenomena and progressive ankylosis - the hallmark ochronotic spondylopathy.
Versus ankylosing spondylitis: AKU is HLA-B27 negative, shows disc calcification rather than syndesmophytes/bamboo spine, and spares the sacroiliac joints relatively early. Black urine on standing is the clincher. AS is HLA-B27 associated with early bilateral sacroiliitis.
Spine first: The collagen-rich intervertebral disc is a favoured site for pigment binding, so axial deposition and calcification occur before peripheral large-joint disease.
Scenario 3: Metabolic Therapy and Its Trade-offs
"An examiner asks you to explain, from biochemistry to clinical trial, how alkaptonuria can be disease-modified and why the treatment is not without cost."
Pathway and block: Tyrosine is degraded via 4-hydroxyphenylpyruvate to homogentisic acid (HGA), then by homogentisate 1,2-dioxygenase (HGD) to maleylacetoacetate. In AKU, HGD is deficient, so HGA accumulates, polymerises and deposits as ochronotic pigment.
Nitisinone: It inhibits the upstream enzyme 4-hydroxyphenylpyruvate dioxygenase (HPPD), so less HGA is produced. SONIA 1 showed a dose-dependent fall in urinary HGA (~99% at 8 mg over 4 weeks); SONIA 2, a 4-year RCT, showed a 99.7% reduction in urinary HGA and significantly slower clinical progression (lower cAKUSSI) with 10 mg daily.
Drawback: Blocking HPPD raises tyrosine (acquired tyrosinosis affecting serum and tissues), risking corneal keratopathy. It is managed with tyrosine monitoring, dietary protein modification and ophthalmic surveillance.
MCQ Practice Points
Enzyme Defect Question
Q: Which enzyme is deficient in alkaptonuria? A: Homogentisate 1,2-dioxygenase (HGD) - an autosomal recessive defect causing accumulation of homogentisic acid.
Diagnostic Test Question
Q: What is the definitive diagnostic test for alkaptonuria? A: Elevated urinary homogentisic acid - the urine also classically turns black on standing or alkalinisation.
Spine Radiograph Question
Q: What is the hallmark spine radiographic finding in ochronosis? A: Multilevel intervertebral disc calcification with disc-space narrowing and vacuum phenomena.
Drug Mechanism Question
Q: What is the mechanism of nitisinone in alkaptonuria? A: Inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD), the upstream enzyme, reducing production of homogentisic acid.
Differential Question
Q: Which feature distinguishes ochronotic spondylopathy from ankylosing spondylitis? A: Dense disc calcification with early sacroiliac sparing and HLA-B27 negativity (versus syndesmophytes and early sacroiliitis in AS).
Side Effect Question
Q: What is the main metabolic side effect of nitisinone therapy? A: Hypertyrosinaemia (acquired tyrosinosis), which can cause sight-threatening corneal keratopathy and requires monitoring.
Guidelines, Registries & Global Practice
Ochronosis is a rare disease, so practice is shaped by specialist centres and rare-disease frameworks rather than mainstream arthroplasty guidelines. The biology is universal; access to diagnosis and to nitisinone is not.
Global Epidemiology
- Alkaptonuria is rare worldwide, with an estimated birth prevalence of roughly 1 in 250,000 to 1 in 1,000,000 in most populations.
- Geographic clusters of much higher prevalence exist, notably in Slovakia and parts of the Dominican Republic, reflecting founder effects in the HGD gene.
- Many distinct pathogenic HGD variants have been catalogued internationally (for example, large variant cohorts described in Russia), underpinning genetic confirmation and family screening.
Therapy Access and Regulatory Status
| Aspect | Position | Practical Implication |
|---|---|---|
| Disease-modifying drug | Nitisinone lowers HGA by ~99% (SONIA trials) | Mainstay where available; needs metabolic supervision |
| Specialist centres | Dedicated AKU services (e.g. UK National Alkaptonuria Centre) | Concentrate expertise, monitoring and dietetics |
| Monitoring requirement | Tyrosine, ophthalmology, dietetics | Mandatory alongside nitisinone |
| Surgical care | Standard arthroplasty principles apply | Plan for multi-joint disease and poor tissue quality |
There is broad consensus that HGA-lowering with nitisinone plus structured monitoring is the rational disease-modifying approach, and that end-stage arthropathy is treated with arthroplasty using conventional principles adapted for stiff joints and friable tissue.
Registries & Surveillance
- No large arthroplasty registry isolates ochronotic arthropathy, but national joint registries (NJR, AJRR, AOANJRR, SHAR, NZJR) capture implant survival data that inform implant choice when these patients require replacement.
- Rare-disease registries and dedicated AKU cohorts (linked to the SONIA programme and patient organisations such as the AKU Society) are the principal source of natural-history and treatment-outcome data.
High- vs Limited-Resource Practice Variation
- High-resource settings: access to genetic confirmation, nitisinone with tyrosine/ophthalmic monitoring, dietetics and elective multi-joint arthroplasty.
- Limited-resource settings: diagnosis is often delayed to the arthroplasty table; management relies on analgesia, physiotherapy and replacement when feasible, with limited access to nitisinone.
OCHRONOSIS (ALKAPTONURIA)
Clinical summary
Biochemistry
- •**Defect**: HGD deficiency (autosomal recessive)
- •**Accumulates**: Homogentisic acid (HGA)
- •**Pigment**: HGA polymer binds collagen (ochronosis)
Clinical / Imaging
- •**Triad**: dark urine, pigmentation, arthropathy
- •**Spine first**: disc calcification + vacuum sign
- •**Spot signs**: scleral/ear pigment, black cartilage
Management
- •**Diagnose**: urinary HGA (definitive)
- •**Disease-modify**: nitisinone (inhibits HPPD)
- •**Caveat**: tyrosinaemia/keratopathy; arthroplasty for end-stage
References
-
Ranganath LR, Psarelli EE, Arnoux JB, et al. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2020. PMID 32822600.
-
Ranganath LR, Milan AM, Hughes AT, et al. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): a randomised, open-label, dose-response study. Ann Rheum Dis. 2014. PMID 25475116.
-
Rajkumar N, Soundarrajan D, Dhanasekararaja P, Rajasekaran S. Clinical and radiological outcomes of total joint arthroplasty in patients with ochronotic arthropathy. Eur J Orthop Surg Traumatol. 2020. PMID 32172376.
-
Khedr M, Cooper MS, Hughes AT, et al. Nitisinone causes acquired tyrosinosis in alkaptonuria. J Inherit Metab Dis. 2020. PMID 32083330.
-
Mistry JB, Bukhari M, Taylor AM. Alkaptonuria. Rare Dis. 2013. PMID 25003018.
-
Grosicka A, Kucharz EJ. Alkaptonuria. Wiad Lek. 2009. PMID 20229718.
-
Soltysova A, Kuzin A, Samarkina E, Zatkova A. Alkaptonuria in Russia. Eur J Hum Genet. 2021. PMID 34504318.